These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
230 related articles for article (PubMed ID: 19461675)
1. Adenovirus delivery of human CD40 ligand gene confers direct therapeutic effects on carcinomas. Vardouli L; Lindqvist C; Vlahou K; Loskog AS; Eliopoulos AG Cancer Gene Ther; 2009 Nov; 16(11):848-60. PubMed ID: 19461675 [TBL] [Abstract][Full Text] [Related]
2. Growth-inhibitory effects of CD40 ligand (CD154) and its endogenous expression in human breast cancer. Tong AW; Papayoti MH; Netto G; Armstrong DT; Ordonez G; Lawson JM; Stone MJ Clin Cancer Res; 2001 Mar; 7(3):691-703. PubMed ID: 11297266 [TBL] [Abstract][Full Text] [Related]
3. Adenovirus-mediated CD40 ligand therapy induces tumor cell apoptosis and systemic immunity in the TRAMP-C2 mouse prostate cancer model. Dzojic H; Loskog A; Tötterman TH; Essand M Prostate; 2006 Jun; 66(8):831-8. PubMed ID: 16491482 [TBL] [Abstract][Full Text] [Related]
4. Antitumor activity of an oncolytic adenoviral-CD40 ligand (CD154) transgene construct in human breast cancer cells. Gomes EM; Rodrigues MS; Phadke AP; Butcher LD; Starling C; Chen S; Chang D; Hernandez-Alcoceba R; Newman JT; Stone MJ; Tong AW Clin Cancer Res; 2009 Feb; 15(4):1317-25. PubMed ID: 19228733 [TBL] [Abstract][Full Text] [Related]
5. Prospects for CD40-directed experimental therapy of human cancer. Tong AW; Stone MJ Cancer Gene Ther; 2003 Jan; 10(1):1-13. PubMed ID: 12489023 [TBL] [Abstract][Full Text] [Related]
6. Combined effects of soluble vascular endothelial growth factor receptor FLT-1 gene therapy and cisplatin chemotherapy in human tongue carcinoma xenografts. Gao ZN; Wei YQ; Yang PS; Xu X; Zhao HQ; Huan X; Kang B Oral Oncol; 2007 May; 43(5):477-83. PubMed ID: 16997614 [TBL] [Abstract][Full Text] [Related]
7. Gene transfer of CD40-ligand to dendritic cells stimulates interferon-gamma production to induce growth arrest and apoptosis of tumor cells. Tomihara K; Kato K; Masuta Y; Nakamura K; Uchida H; Sasaki K; Tanaka T; Huang J; Hiratsuka H; Hamada H Gene Ther; 2008 Feb; 15(3):203-13. PubMed ID: 17989706 [TBL] [Abstract][Full Text] [Related]
8. Growth inhibition of human multiple myeloma cells by an oncolytic adenovirus carrying the CD40 ligand transgene. Fernandes MS; Gomes EM; Butcher LD; Hernandez-Alcoceba R; Chang D; Kansopon J; Newman J; Stone MJ; Tong AW Clin Cancer Res; 2009 Aug; 15(15):4847-56. PubMed ID: 19622582 [TBL] [Abstract][Full Text] [Related]
9. Adeno-associated virus mediated gene transfer into lung cancer cells promoting CD40 ligand-based immunotherapy. Wu JQ; Zhao WH; Li Y; Zhu B; Yin KS Virology; 2007 Nov; 368(2):309-16. PubMed ID: 17675129 [TBL] [Abstract][Full Text] [Related]
10. Comparative analysis of antitumor activity of CD40L, RANKL, and 4-1BBL in vivo following intratumoral administration of viral vectors or transduced dendritic cells. Yurkovetsky ZR; Shurin GV; Barry DA; Schuh AC; Shurin MR; Robbins PD J Gene Med; 2006 Feb; 8(2):129-37. PubMed ID: 16288496 [TBL] [Abstract][Full Text] [Related]
11. PNAS-4, a novel pro-apoptotic gene, can potentiate antineoplastic effects of cisplatin. Yuan Z; Yan F; Wang YS; Liu HY; Gou LT; Zhao XY; Lai ST; Deng HX; Li J; Ding ZY; Xiong SQ; Kan B; Mao YQ; Chen LJ; Wei YQ; Zhao X Cancer Chemother Pharmacol; 2009 Dec; 65(1):13-25. PubMed ID: 19387645 [TBL] [Abstract][Full Text] [Related]
12. Recombinant CD40 ligand therapy has significant antitumor effects on CD40-positive ovarian tumor xenografts grown in SCID mice and demonstrates an augmented effect with cisplatin. Ghamande S; Hylander BL; Oflazoglu E; Lele S; Fanslow W; Repasky EA Cancer Res; 2001 Oct; 61(20):7556-62. PubMed ID: 11606394 [TBL] [Abstract][Full Text] [Related]
13. Immuno-gene therapy with adenoviruses expressing fms-like tyrosine kinase 3 ligand and CD40 ligand for mouse hepatoma cells in vivo. Yanagi K; Nagayama Y; Nakao K; Saeki A; Matsumoto K; Ichikawa T; Ishikawa H; Hamasaki K; Ishii N; Eguchi K Int J Oncol; 2003 Feb; 22(2):345-51. PubMed ID: 12527933 [TBL] [Abstract][Full Text] [Related]
14. Expression of CD40 and growth-inhibitory activity of CD40 ligand in colon cancer ex vivo. Wu Y; Wang L; He X; Xu H; Zhou L; Zhao F; Zhang Y Cell Immunol; 2008; 253(1-2):102-9. PubMed ID: 18603231 [TBL] [Abstract][Full Text] [Related]
15. Transgenic expression of CD40L and interleukin-2 induces an autologous antitumor immune response in patients with non-Hodgkin's lymphoma. Takahashi S; Yotnda P; Rousseau RF; Mei Z; Smith S; Rill D; Younes A; Brenner MK Cancer Gene Ther; 2001 May; 8(5):378-87. PubMed ID: 11477458 [TBL] [Abstract][Full Text] [Related]
16. Efficient gene transfer of CD40 ligand into ovarian carcinoma cells with a recombinant adeno-associated virus vector. Koppold B; Sauer G; Büning H; Hallek M; Kreienberg R; Deissler H; Kurzeder C Int J Oncol; 2005 Jan; 26(1):95-101. PubMed ID: 15586229 [TBL] [Abstract][Full Text] [Related]
17. Local AdCD40L gene therapy is effective for disseminated murine experimental cancer by breaking T-cell tolerance and inducing tumor cell growth inhibition. Lindqvist C; Sandin LC; Fransson M; Loskog A J Immunother; 2009 Oct; 32(8):785-92. PubMed ID: 19752755 [TBL] [Abstract][Full Text] [Related]
18. Gene therapy using TRAIL-secreting human umbilical cord blood-derived mesenchymal stem cells against intracranial glioma. Kim SM; Lim JY; Park SI; Jeong CH; Oh JH; Jeong M; Oh W; Park SH; Sung YC; Jeun SS Cancer Res; 2008 Dec; 68(23):9614-23. PubMed ID: 19047138 [TBL] [Abstract][Full Text] [Related]
19. Oncolytic adenovirus-mediated shRNA against Apollon inhibits tumor cell growth and enhances antitumor effect of 5-fluorouracil. Chu L; Gu J; Sun L; Qian Q; Qian C; Liu X Gene Ther; 2008 Apr; 15(7):484-94. PubMed ID: 18239605 [TBL] [Abstract][Full Text] [Related]
20. Immune response is an important aspect of the antitumor effect produced by a CD40L-encoding oncolytic adenovirus. Diaconu I; Cerullo V; Hirvinen ML; Escutenaire S; Ugolini M; Pesonen SK; Bramante S; Parviainen S; Kanerva A; Loskog AS; Eliopoulos AG; Pesonen S; Hemminki A Cancer Res; 2012 May; 72(9):2327-38. PubMed ID: 22396493 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]